|
|
|
|
|
|
26 March 2026
PFAS restrictions: risks for patients and companies operating in Europe
EFPIA reaction to the publication of ECHA scientific committees’ opinions on PFAS Restriction.
|
||
|
|
24 March 2026
World TB Day 2026: Working together to end tuberculosis (Guest blog)
Tuberculosis (TB) remains the world’s deadliest infectious diseases. Not only do more than 10 million people fall ill...
|
||
|
|
On 24 March, EFPIA took part in POLITICO’s Competitive Europe Summit, at a pivotal moment for Europe’s future. With the EU at a crossroads, discussions focused on whether Europe can reform, drive growth and reclaim global influence - or risk stagnation, undermining both its economic strength and security.
Stefan Oelrich, EFPIA President and President of Pharmaceuticals at Bayer AG underscored both Europe’s strengths and the urgency to act: “Europe has the science, the skills and a strong industrial base, but we’re being outpaced by China and the United States on investment, clinical trials and advancing novel medicines. Europe’s challenge is to close the gaps identified in the report to create an environment that attracts investment, accelerates translation into new treatments and ensures day-one access for Europeans. If we’re willing to act to close the gap, we don’t just boost growth; we secure Europe’s health resilience. The choice is ours.” ➡️ Watch the highlight from Stefan Oelrich’s opening remarks.
In a fireside chat on Europe’s global competitiveness in pharmaceuticals, Padraic Ward, Head of Roche Pharma International, highlighted the need for a critical mindset shift. In Europe, “health [is] being thought about as a cost and not as an investment,” ➡️ Watch a short highlight from the fireside chat: Can Europe lead the world’s pharma market? with Padraic Ward.
|
|
|
Europe’s Choice: Investing in sustainable health systems
Brussels, Belgium
At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening,... Learn more → |
|||
|
European Pharmaceutical Law Forum
Brussels, Belgium
The European pharmaceutical market is facing a moment of profound change. With sweeping updates to the EU pharmaceutical... Learn more → |
|||
|
|
Swedish study: HPV vaccines protect against cervical cancer after 18 years
25 March 2026 (Vaccines Today)
More reassuring news from long-term study following 926,362 girls and women for almost two decades.
|
|
Europe cannot afford to leave Alzheimer’s patients behind
24 March 2026 (POLITICO)
Time is running out. If Europe acts now on this disease, it can help more people age with dignity while supporting...
|
|
What the EU Biotech Act delivers for Europe
20 March 2026 (POLITICO)
Biotechnology drives cutting-edge medical innovation but is constrained by Europe’s fragmented regulatory landscape....
|
|
Turning the tide on cardiovascular diseases
03 March 2026 (Vaccines Europe)
Cardiovascular diseases (CVD) claim over 1.8 million lives across Europe every year. Behind this number are millions...
|
|
|||
|
|||||
|
EFPIA 2026 All rights reserved ·
Disclaimer
·
|